Center-Authored Papers

Filters: Author is Allen, Mary  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Moodie Z, Metch B, Bekker L-G, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C et al..  2015.  Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.. PloS one. 10(9):e0137666. Abstract
F
Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams SA, Tomaras GD et al..  2015.  First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).. Open forum infectious diseases. 2(3):ofv082. Abstract
R
Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker L-G, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S et al..  2014.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.. The Lancet infectious diseases. 14(5):388-96. Abstract
S
Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I et al..  2013.  Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery.. The Journal of infectious diseases. 208(5):818-29. Abstract
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker L-G, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH et al..  2011.  Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.. The Lancet infectious diseases. 11(7):507-15. Abstract
Spearman P, Kalams S, Elizaga M, Metch B, Chiu Y-L, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ et al..  2009.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.. Vaccine. 27(2):243-9. Abstract
Churchyard G, Mlisana K, Karuna S, Williamson A-L, Williamson C, Morris L, Tomaras GD, De Rosa SC, Gilbert PB, Gu N et al..  2016.  Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.. PloS one. 11(9):e0161753. Abstract
Gray GE, Mayer KH, Elizaga ML, Bekker L-G, Allen M, Morris L, Montefiori D, De Rosa SC, Sato A, Gu N et al..  2016.  Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.. Clinical and vaccine immunology : CVI. 23(6):496-506. Abstract